Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

MediWound (MDWD) Other Non-Current Liabilities: 2013-2024

Historic Other Non-Current Liabilities for MediWound (MDWD) over the last 11 years, with Sep 2024 value amounting to -$2.8 million.

  • MediWound's Other Non-Current Liabilities fell 218.38% to -$2.8 million in Q3 2024 from the same period last year, while for Sep 2024 it was -$2.8 million, marking a year-over-year decrease of 218.38%. This contributed to the annual value of $2.3 million for FY2023, which is 85.54% down from last year.
  • Latest data reveals that MediWound reported Other Non-Current Liabilities of -$2.8 million as of Q3 2024, which was down 244.44% from $2.0 million recorded in Q2 2024.
  • MediWound's 5-year Other Non-Current Liabilities high stood at $15.6 million for Q4 2022, and its period low was -$2.8 million during Q3 2024.
  • Over the past 3 years, MediWound's median Other Non-Current Liabilities value was $2.5 million (recorded in 2023), while the average stood at $3.3 million.
  • In the last 5 years, MediWound's Other Non-Current Liabilities skyrocketed by 297.91% in 2022 and then crashed by 218.38% in 2024.
  • MediWound's Other Non-Current Liabilities (Quarterly) stood at $5.0 million in 2020, then declined by 21.53% to $3.9 million in 2021, then surged by 297.91% to $15.6 million in 2022, then plummeted by 85.54% to $2.3 million in 2023, then slumped by 218.38% to -$2.8 million in 2024.
  • Its last three reported values are -$2.8 million in Q3 2024, $2.0 million for Q2 2024, and $2.1 million during Q1 2024.